BEAT - HeartBeam Inc. (NASDAQ: BEAT) CEO Spotlighted in Interview on Making a Positive Social Impact
- During interview, Vajdic recounts first steps of journey in the United States
- CEO points to key lessons he learned that helped him found HeartBeam
- The company has developed the first and only 3D-vector 12-lead electrocardiogram (“ECG”) platform for heart attack detection anytime, anywhere
Growing up in Yugoslavia (now Serbia) as the only child of a well-known surgeon, HeartBeam (NASDAQ: BEAT) CEO and founder Branislav Vajdic, PhD, felt some pressure to study medicine and follow in his father’s footsteps. One day, at his father’s insistence, Vajdic observed a surgery — and fainted the moment he saw the first drop of blood. While that experience confirmed to Vajdic that medicine was not for him, decades later he is making his mark in the field of the detection and treatment of heart attacks.
“I was always fascinated with electronics; that was clearly my path,” said Vajdic during a recent “Authority Magazine” interview with David Leichner, part of an interview series focused on technology companies working to...
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at http://ibn.fm/BEAT
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "Biotech" to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.